GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BB Biotech AG (GREY:BBAGF) » Definitions » Cyclically Adjusted FCF per Share

BB Biotech AG (BB Biotech AG) Cyclically Adjusted FCF per Share : $4.07 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is BB Biotech AG Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

BB Biotech AG's adjusted free cash flow per share for the three months ended in Dec. 2023 was $-0.020. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $4.07 for the trailing ten years ended in Dec. 2023.

During the past 12 months, BB Biotech AG's average Cyclically Adjusted FCF Growth Rate was 20.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-05-15), BB Biotech AG's current stock price is $46.50. BB Biotech AG's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $4.07. BB Biotech AG's Cyclically Adjusted Price-to-FCF of today is 11.43.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of BB Biotech AG was 22.52. The lowest was 17.06. And the median was 18.67.


BB Biotech AG Cyclically Adjusted FCF per Share Historical Data

The historical data trend for BB Biotech AG's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BB Biotech AG Cyclically Adjusted FCF per Share Chart

BB Biotech AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 3.38 4.07

BB Biotech AG Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Dec17 Dec18 Dec19 Dec20 Mar21 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.38 4.19 4.11 4.18 4.07

Competitive Comparison of BB Biotech AG's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, BB Biotech AG's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BB Biotech AG's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BB Biotech AG's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where BB Biotech AG's Cyclically Adjusted Price-to-FCF falls into.



BB Biotech AG Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BB Biotech AG's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.02/106.4611*106.4611
=-0.020

Current CPI (Dec. 2023) = 106.4611.

BB Biotech AG Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201106 0.000 102.678 0.000
201109 1.095 101.811 1.145
201112 0.382 101.408 0.401
201203 1.698 101.826 1.775
201206 -0.133 101.596 -0.139
201209 2.532 101.392 2.659
201212 0.387 100.968 0.408
201303 1.053 101.221 1.108
201306 1.977 101.466 2.074
201309 -0.642 101.336 -0.674
201312 1.421 101.036 1.497
201403 -0.232 101.224 -0.244
201406 0.065 101.517 0.068
201409 0.431 101.247 0.453
201412 1.945 100.704 2.056
201503 3.209 100.339 3.405
201506 2.873 100.464 3.045
201509 -3.508 99.785 -3.743
201512 -1.522 99.386 -1.630
201603 -0.393 99.475 -0.421
201606 0.272 100.088 0.289
201609 2.280 99.604 2.437
201612 0.015 99.380 0.016
201703 0.945 100.040 1.006
201706 5.973 100.285 6.341
201712 0.000 100.213 0.000
201812 0.000 100.906 0.000
201912 0.000 101.063 0.000
202012 0.000 100.241 0.000
202103 -1.943 100.800 -2.052
202106 1.000 101.352 1.050
202112 0.000 101.776 0.000
202203 4.308 103.205 4.444
202206 0.699 104.783 0.710
202209 0.618 104.835 0.628
202212 -1.180 104.666 -1.200
202303 4.002 106.245 4.010
202306 0.173 106.576 0.173
202309 0.151 106.570 0.151
202312 -0.020 106.461 -0.020

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


BB Biotech AG  (GREY:BBAGF) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

BB Biotech AG's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=46.50/4.07
=11.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of BB Biotech AG was 22.52. The lowest was 17.06. And the median was 18.67.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


BB Biotech AG Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of BB Biotech AG's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


BB Biotech AG (BB Biotech AG) Business Description

Industry
Traded in Other Exchanges
Address
Schwertstrasse 6, Schaffhausen, CHE, CH-8200
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market and is one of the largest investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. BB Biotech follows a strategy of carefully screening and selecting biotechnology firms with a long-term time horizon and having established products in the marketplace. Geographically it earns key revenue from the Netherlands.

BB Biotech AG (BB Biotech AG) Headlines

No Headlines